Analysis of Pretreatment FDG-PET SUV Parameters in Head-and-Neck Cancer: Tumor SUVmean Has Superior Prognostic Value
Creators
- 1. Department of Radiation Oncology, Duke University Medical Center, Durham, NC (United States)
- 2. Department of Radiology, Division of Neuroradiology, Duke University Medical Center, Durham, NC (United States)
- 3. Graduate Program in Medical Physics, Duke University Medical Center, Durham, NC (United States)
- 4. Department of Biomedical Engineering, Duke University Medical Center, Durham, NC (United States)
- 5. Department of Radiology, Division of Nuclear Medicine, Duke University Medical Center, Durham, NC (United States)
- 6. Department of Surgery, Division of Head and Neck Surgery, Duke University Medical Center, Durham, NC (United States)
Description
Purpose: To evaluate the prognostic significance of different descriptive parameters in head-and-neck cancer patients undergoing pretreatment [F-18] fluoro-D-glucose-positron emission tomography (FDG-PET) imaging. Patients and Methods: Head-and-neck cancer patients who underwent FDG-PET before a course of curative intent radiotherapy were retrospectively analyzed. FDG-PET imaging parameters included maximum (SUVmax), and mean (SUVmean) standard uptake values, and total lesion glycolysis (TLG). Tumors and lymph nodes were defined on co-registered axial computed tomography (CT) slices. SUVmax and SUVmean were measured within these anatomic regions. The relationships between pretreatment SUVmax, SUVmean, and TLG for the primary site and lymph nodes were assessed using a univariate analysis for disease-free survival (DFS), locoregional control (LRC), and distant metastasis-free survival (DMFS). Kaplan-Meier survival curves were generated and compared via the log‒rank method. SUV data were analyzed as continuous variables. Results: A total of 88 patients was assessed. Two-year OS, LRC, DMFS, and DFS for the entire cohort were 85%, 78%, 81%, and 70%, respectively. Median SUVmax for the primary tumor and lymph nodes was 15.4 and 12.2, respectively. Median SUVmean for the primary tumor and lymph nodes was 7 and 5.2, respectively. Median TLG was 770. Increasing pretreatment SUVmean of the primary tumor was associated with decreased disease-free survival (p = 0.01). Neither SUVmax in the primary tumor or lymph nodes nor TLG was prognostic for any of the clinical endpoints. Patients with pretreatment tumor SUVmean that exceeded the median value (7) of the cohort demonstrated inferior 2-year DFS relative to patients with SUVmean ≤ the median value of the cohort, 58% vs. 82%, respectively, p = 0.03. Conclusion: Increasing SUVmean in the primary tumor was associated with inferior DFS. Although not routinely reported, pretreatment SUVmean may be a useful prognostic FDG-PET parameter and should be further evaluated prospectively.
Availability note (English)
Available from http://dx.doi.org/10.1016/j.ijrobp.2010.11.050Additional details
Identifiers
- DOI
- 10.1016/j.ijrobp.2010.11.050;
- PII
- S0360-3016(10)03673-4;
Publishing Information
- Journal Title
- International Journal of Radiation Oncology, Biology and Physics
- Journal Volume
- 82
- Journal Issue
- 2
- Journal Page Range
- p. 548-553
- ISSN
- 0360-3016
- CODEN
- IOBPD3
INIS
- Country of Publication
- United States
- Country of Input or Organization
- International Atomic Energy Agency (IAEA)
- INIS RN
- 44016374
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- FLUORINE 18; GLUCOSE; GLYCOLYSIS; HEAD; LYMPH NODES; METASTASES; NECK; NEOPLASMS; PATIENTS; POSITRON COMPUTED TOMOGRAPHY; RADIOTHERAPY; STANDARDS; SURVIVAL CURVES
- Descriptors DEC
- ALDEHYDES; BETA DECAY RADIOISOTOPES; BETA-PLUS DECAY RADIOISOTOPES; BODY; CARBOHYDRATES; CHEMICAL REACTIONS; COMPUTERIZED TOMOGRAPHY; DECOMPOSITION; DIAGNOSTIC TECHNIQUES; DISEASES; EMISSION COMPUTED TOMOGRAPHY; FLUORINE ISOTOPES; HEXOSES; HOURS LIVING RADIOISOTOPES; ISOMERIC TRANSITION ISOTOPES; ISOTOPES; LIGHT NUCLEI; LYMPHATIC SYSTEM; MEDICINE; METABOLISM; MONOSACCHARIDES; NANOSECONDS LIVING RADIOISOTOPES; NUCLEAR MEDICINE; NUCLEI; ODD-ODD NUCLEI; ORGANIC COMPOUNDS; RADIOISOTOPES; RADIOLOGY; SACCHARIDES; THERAPY; TOMOGRAPHY
Optional Information
- Copyright
- Copyright (c) 2012 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.